Market Overview:
The global ormetoprim market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising demand for animal feed additives, increasing awareness about animal health and hygiene, and growing demand for organic meat products. However, the growth of the market could be restrained by factors such as stringent regulations governing the use of ormetoprim. The global ormetoprim market is segmented on the basis of type, application, and region.
Product Definition:
Ormetoprim is a sulfonamide antibiotic used to treat urinary tract infections. It is also used for prophylaxis of urinary tract infections in patients undergoing instrumentation.
?98.5%:
?98.5% is a concentration of OMP used in the treatment of malaria, and has been found to be more effective than the traditional ?90% concentration. It is also used as an off-label drug for other diseases such as Chagas disease, American trypanosomiasis (sleeping sickness), and African trypanosomiasis (sleeping sickness).
98.5% is the concentration of OMP which has a better effect on patients with low or no fundus seen in first 24 hours and second-generation cephalosporin drugs are used for its treatment.
OMP is used to treat bacterial meningitis, bloodstream infections, septicaemia and pneumonia caused by various bacteria including K. pneumoniae (meningococcal meningitis), E. coli (septicaemia) and P.
Application Insights:
The animals segment held the largest share of more than 60.0% in 2017. The application of OMP is widespread for the treatment of various diseases in animals, such as swine dysentery, rinderpest, and salmonella infections in poultry. Moreover, it is also used to treat parasitic diseases caused by hookworms and Ascaris lumbricoides among other nematodes affecting humans such as trichuriasis or whipworm infection among children. Thus, rising importance on animal health coupled with increasing incidences of infectious diseases will drive demand over the forecast period.
Application II includes human use which accounted for a smaller market share due to high cost associated with its usage along with other antifungal agents like ketoconazole and itraconazole that are cheaper alternatives for treating fungal infections in humans without causing liver damage or interactions with other drugs (antibiotics).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high adoption rate for new therapies are some of the factors responsible for its large share. In addition, increasing number of animals affected with orthopedic disorders is expected to drive the regional market during the forecast period.
Asia Pacific is anticipated to be one of fastest-growing regions owing to rising healthcare expenditure and improving access due to rise in disposable income levels coupled with increase in government initiatives such as “Healthcare Reform†initiated by China's former president Jiang Zemin (1993). This initiative aims at universal coverage through private insurance system rather than relying on public health systems which would reduce overall healthcare costs over time; this has led Asia Pacific region poised for significant growth opportunities during the forecast period.
Growth Factors:
- The increasing demand for antibiotics owing to the growing prevalence of infectious diseases is expected to drive the growth of the Ormetoprim market.
- The rising awareness about the benefits of using antibiotics is anticipated to boost the demand for Ormetoprim products during the forecast period.
- The increasing investment by pharmaceutical companies in research and development activities for new antibiotic drugs is projected to propel the growth of this market in future.
- Growing number of mergers and acquisitions among key players is likely to provide impetus to this market over next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ormetoprim(OMP) Market Research Report
By Type
?98.5%, <98.5%
By Application
Animals, Application II
By Companies
PCCPL, Tianhe Pharmaceutical, CoreSyn, Yangzhou Winsome Aba Pharmacy, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Ormetoprim(OMP) Market Report Segments:
The global Ormetoprim(OMP) market is segmented on the basis of:
Types
?98.5%, <98.5%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Animals, Application II
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- PCCPL
- Tianhe Pharmaceutical
- CoreSyn
- Yangzhou Winsome Aba Pharmacy
- ...
Highlights of The Ormetoprim(OMP) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ?98.5%
- <98.5%
- By Application:
- Animals
- Application II
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ormetoprim(OMP) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ormetoprim is an antibiotic used to treat a variety of infections, including pneumonia. It is also used to prevent or treat malaria.
Some of the key players operating in the ormetoprim(omp) market are PCCPL, Tianhe Pharmaceutical, CoreSyn, Yangzhou Winsome Aba Pharmacy.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ormetoprim(OMP) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ormetoprim(OMP) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ormetoprim(OMP) Market - Supply Chain
4.5. Global Ormetoprim(OMP) Market Forecast
4.5.1. Ormetoprim(OMP) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ormetoprim(OMP) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ormetoprim(OMP) Market Absolute $ Opportunity
5. Global Ormetoprim(OMP) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ormetoprim(OMP) Market Size and Volume Forecast by Type
5.3.1. ?98.5%
5.3.2. <98.5%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ormetoprim(OMP) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ormetoprim(OMP) Market Size and Volume Forecast by Application
6.3.1. AnimalsII
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ormetoprim(OMP) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ormetoprim(OMP) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ormetoprim(OMP) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ormetoprim(OMP) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ormetoprim(OMP) Demand Share Forecast, 2019-2029
9. North America Ormetoprim(OMP) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ormetoprim(OMP) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ormetoprim(OMP) Market Size and Volume Forecast by Application
9.4.1. AnimalsII
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ormetoprim(OMP) Market Size and Volume Forecast by Type
9.7.1. ?98.5%
9.7.2. <98.5%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ormetoprim(OMP) Demand Share Forecast, 2019-2029
10. Latin America Ormetoprim(OMP) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ormetoprim(OMP) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ormetoprim(OMP) Market Size and Volume Forecast by Application
10.4.1. AnimalsII
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ormetoprim(OMP) Market Size and Volume Forecast by Type
10.7.1. ?98.5%
10.7.2. <98.5%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ormetoprim(OMP) Demand Share Forecast, 2019-2029
11. Europe Ormetoprim(OMP) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ormetoprim(OMP) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ormetoprim(OMP) Market Size and Volume Forecast by Application
11.4.1. AnimalsII
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ormetoprim(OMP) Market Size and Volume Forecast by Type
11.7.1. ?98.5%
11.7.2. <98.5%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type 11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ormetoprim(OMP) Demand Share, 2019-2029
12. Asia Pacific Ormetoprim(OMP) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ormetoprim(OMP) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ormetoprim(OMP) Market Size and Volume Forecast by Application
12.4.1. AnimalsII
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ormetoprim(OMP) Market Size and Volume Forecast by Type
12.7.1. ?98.5%
12.7.2. <98.5%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ormetoprim(OMP) Demand Share, 2019-2029
13. Middle East & Africa Ormetoprim(OMP) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ormetoprim(OMP) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ormetoprim(OMP) Market Size and Volume Forecast by Application
13.4.1. AnimalsII
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ormetoprim(OMP) Market Size and Volume Forecast by Type
13.7.1. ?98.5%
13.7.2. <98.5%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ormetoprim(OMP) Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Ormetoprim(OMP) Market: Market Share Analysis
14.2. Ormetoprim(OMP) Distributors and Customers
14.3. Ormetoprim(OMP) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. PCCPL
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Tianhe Pharmaceutical
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CoreSyn
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Yangzhou Winsome Aba Pharmacy
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ...
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook